Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors

Open access

Abstract

Background: Hyperactivation of the Ras signaling pathway is a driver of many cancers, and RAS pathway activation can predict response to targeted therapies. Therefore, optimal methods for measuring Ras pathway activation are critical. The main focus of our work was to develop a gene expression signature that is predictive of RAS pathway dependence. Methods: We used the coherent expression of RAS pathway-related genes across multiple datasets to derive a RAS pathway gene expression signature and generate RAS pathway activation scores in pre-clinical cancer models and human tumors. We then related this signature to KRAS mutation status and drug response data in pre-clinical and clinical datasets. Results: The RAS signature score is predictive of KRAS mutation status in lung tumors and cell lines with high (> 90%) sensitivity but relatively low (50%) specificity due to samples that have apparent RAS pathway activation in the absence of a KRAS mutation. In lung and breast cancer cell line panels, the RAS pathway signature score correlates with pMEK and pERK expression, and predicts resistance to AKT inhibition and sensitivity to MEK inhibition within both KRAS mutant and KRAS wild-type groups. The RAS pathway signature is upregulated in breast cancer cell lines that have acquired resistance to AKT inhibition, and is downregulated by inhibition of MEK. In lung cancer cell lines knockdown of KRAS using siRNA demonstrates that the RAS pathway signature is a better measure of dependence on RAS compared to KRAS mutation status. In human tumors, the RAS pathway signature is elevated in ER negative breast tumors and lung adenocarcinomas, and predicts resistance to cetuximab in metastatic colorectal cancer. Conclusions: These data demonstrate that the RAS pathway signature is superior to KRAS mutation status for the prediction of dependence on RAS signaling, can predict response to PI3K and RAS pathway inhibitors, and is likely to have the most clinical utility in lung and breast tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1755-8794-3-26

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 RAS signature score relationship to Kras mutation status. RAS signature scores relative to KRAS mutation status in (A) lung cancer cell lines, (B) breast cancer cell lines, and (C) lung tumors. The Y-axis shows the RAS pathway signature score relative to the mean of all samples in the experiment. Samples in red are KRAS mutant, samples in blue are KRAS wild-type
Figure 1 RAS signature score relationship to Kras mutation status. RAS signature scores relative to KRAS mutation status in (A) lung cancer cell lines, (B) breast cancer cell lines, and (C) lung tumors. The Y-axis shows the RAS pathway signature score relative to the mean of all samples in the experiment. Samples in red are KRAS mutant, samples in blue are KRAS wild-typeCC BY · PubMed Central
Figure 2 RAS signature versus drug sensitivity or pathway activation. RAS signature score (Y-axis) versus cell sensitivity to a MEK inhibition (X-axis) across a panel of (A) lung or (B) breast cell lines. Lower numbers on the X-axis indicate increasing sensitivity. Cell lines circled in bold in (A) have a KRAS mutation but have low signature scores and are resistant to MEK inhibition. (C) RAS signature score (Y-axis) versus cell sensitivity to an AKT inhibitor (X-axis) across a panel of breast cancer cell lines. Lower numbers on the X-axis indicate increasing sensitivity. (D) phospho-MEK (Y-axis) versus RAS signature score (X-axis) across a panel of breast cancer cell lines. In all cases, the RAS signature score was calculated relative to the mean of all cell lines in the respective experiment. R = Pearson correlation coefficient, p = the corresponding P-value.
Figure 2 RAS signature versus drug sensitivity or pathway activation. RAS signature score (Y-axis) versus cell sensitivity to a MEK inhibition (X-axis) across a panel of (A) lung or (B) breast cell lines. Lower numbers on the X-axis indicate increasing sensitivity. Cell lines circled in bold in (A) have a KRAS mutation but have low signature scores and are resistant to MEK inhibition. (C) RAS signature score (Y-axis) versus cell sensitivity to an AKT inhibitor (X-axis) across a panel of breast cancer cell lines. Lower numbers on the X-axis indicate increasing sensitivity. (D) phospho-MEK (Y-axis) versus RAS signature score (X-axis) across a panel of breast cancer cell lines. In all cases, the RAS signature score was calculated relative to the mean of all cell lines in the respective experiment. R = Pearson correlation coefficient, p = the corresponding P-value.CC BY · PubMed Central
Figure 3 Acquired resistance to AKT inhibition is associated with increased RAS signature. (A) generation of a cell line with acquired resistance to MK-2206 by culturing in increasing drug concentrations over 7 months. (B) Cells cultured in vehicle for 7 months remain sensitive to AKT inhibition. Cells with acquired resistance to MK-2206 show decreased pAKT (C) and increased pERK (D).
Figure 3 Acquired resistance to AKT inhibition is associated with increased RAS signature. (A) generation of a cell line with acquired resistance to MK-2206 by culturing in increasing drug concentrations over 7 months. (B) Cells cultured in vehicle for 7 months remain sensitive to AKT inhibition. Cells with acquired resistance to MK-2206 show decreased pAKT (C) and increased pERK (D).CC BY · PubMed Central
Figure 4 Effect of KRAS knockdown on viability of cells harboring a KRAS mutation. (A) KRAS mutant or (B) KRAS wild-type cells were selected for KRAS knockdown. Scatterplots indicate that these lines show variable sensitivity to MEK inhibition. The Y-axis shows RAS siganture score, and the X-axis show cell sensitivity to MEK inhibition. Lower numbers on the X-axis indicate increasing sensitivity. Cell lines in red text were treated with siRNAs targeting KRAS. Western blots were performed for KRAS and B-actin. Control = Dharmacon non-targeting siRNA pool; KRAS = siRNA targeting KRAS, none = no transfection. Bar charts show viability as measured by the ATP vialight assay. The percent viability relative to the control siRNA is shown. R = Pearson correlation coefficient, p = the corresponding P-value.
Figure 4 Effect of KRAS knockdown on viability of cells harboring a KRAS mutation. (A) KRAS mutant or (B) KRAS wild-type cells were selected for KRAS knockdown. Scatterplots indicate that these lines show variable sensitivity to MEK inhibition. The Y-axis shows RAS siganture score, and the X-axis show cell sensitivity to MEK inhibition. Lower numbers on the X-axis indicate increasing sensitivity. Cell lines in red text were treated with siRNAs targeting KRAS. Western blots were performed for KRAS and B-actin. Control = Dharmacon non-targeting siRNA pool; KRAS = siRNA targeting KRAS, none = no transfection. Bar charts show viability as measured by the ATP vialight assay. The percent viability relative to the control siRNA is shown. R = Pearson correlation coefficient, p = the corresponding P-value.CC BY · PubMed Central
Figure 5 Impact of MEK inhibition on the RAS signature across 10 lung cancer cell lines. The Y-axis shows the RAS signature score in drug treated cell lines relative to vehicle treated controls.
Figure 5 Impact of MEK inhibition on the RAS signature across 10 lung cancer cell lines. The Y-axis shows the RAS signature score in drug treated cell lines relative to vehicle treated controls.CC BY · PubMed Central
Figure 6 Waterfall plot of RAS signature score in patients who experienced disease control (blue) or progressive disease (red) after Cetuximab therapy. The Y-axis shows RAS signature score relative to the mean of all tumors in this dataset. Fisher's exact test p-value for the difference between the disease control and progressive disease groups is shown. Data is derived from [5], and includes all patients with known response.
Figure 6 Waterfall plot of RAS signature score in patients who experienced disease control (blue) or progressive disease (red) after Cetuximab therapy. The Y-axis shows RAS signature score relative to the mean of all tumors in this dataset. Fisher's exact test p-value for the difference between the disease control and progressive disease groups is shown. Data is derived from [5], and includes all patients with known response.CC BY · PubMed Central
Figure 7 RAS signature distribution across non-small cell lung (A) and breast (B) cancer subsets. The Y-axis shows RAS signature score relative to the mean of all non-small cell lung (A) or breast (B) tumors in the dataset. For (B), GGI = genomic grade index [32]. GGI- = ER positive, GGI negative (surrogate for luminal A). TN = triple negative. Her2 + = high expression of Her2. GGI + = ER positive, GGI high (surrogate for luminal B).
Figure 7 RAS signature distribution across non-small cell lung (A) and breast (B) cancer subsets. The Y-axis shows RAS signature score relative to the mean of all non-small cell lung (A) or breast (B) tumors in the dataset. For (B), GGI = genomic grade index [32]. GGI- = ER positive, GGI negative (surrogate for luminal A). TN = triple negative. Her2 + = high expression of Her2. GGI + = ER positive, GGI high (surrogate for luminal B).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 30 references

Research works printed but not linked: 2

  1. Yan L: MK-2206: A potent oral allosteric AKT inhibitor. American Association for Cancer Research; April 19; Denver, CO. 2009
  2. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al: Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. J Natl Cancer Inst. 2006, 98: 262-272. 10.1093/jnci/djj052. · DOI · Paper page

Cited by

See all 163

Metadata

Authors
Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., Andersen, J., Nagashima, K., Paweletz, C., Lynch, B., Feldman, I., Dai, H., Huang, P., & Watters, J.
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Watters, James
Venue
BMC Medical Genomics
Published
2010-06-30
Volume
3
Issue
1
Pages
26-26
ISSN
1755-8794 (ISSN-L)
OpenAlex
W2022577155
Cited by
152
References
30
Citations by year
2026: 3 · 2025: 4 · 2024: 6 · 2023: 8 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 11 · 2018: 12 · 2017: 14 · 2016: 14 · 2015: 12 · 2014: 14 · 2013: 10 · 2012: 13
FWCI
4.43
Type
journal article
Language
en
Open access
Locations
  • BMC Medical Genomics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Moffitt Cancer Center
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
RAS pathway activation, gene expression signatures, KRAS mutation status, PI3K inhibitors, MEK inhibitors, AKT inhibition, drug response prediction, lung cancer, breast cancer, lung adenocarcinoma, cetuximab resistance, colorectal cancer
MeSH terms
Cetuximab, Phosphoinositide-3 Kinase Inhibitors, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Inhibitors, Female, Humans, Lung Neoplasms, Mutation, Neoplasms, Proto-Oncogene Proteins, Colorectal Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Gene Expression Profiling, Mitogen-Activated Protein Kinase Kinases, Databases, Genetic, RNA Interference, RNA, Small Interfering, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. https://app.cochat.ai/papers/10.1186/1755-8794-3-26
The paper
Loboda, A., Nebozhyn, M., Klinghoffer, R., Frazier, J., Chastain, M., Arthur, W., Roberts, B., Zhang, T., Chenard, M., Haines, B., Andersen, J., Nagashima, K., Paweletz, C., Lynch, B., Feldman, I., Dai, H., Huang, P., & Watters, J. (2010). A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics. https://doi.org/10.1186/1755-8794-3-26

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.